AstraZeneca 2020 - Search News

FDA approves 1st at-home flu vaccine in U.S., a nasal spray

FDA approves a first-of-a-kind flu vaccine in the form of a nasal spray!

In a first, the Food and Drug Administration on Friday approved AstraZeneca's FluMist, a nasal spray flu vaccine that anyone can self-administer.

AFP on MSN · 1d

No doctor necessary: US okays nasal spray flu vaccine for self-use

No doctor? No problem. In a first, the US Food and Drug Administration on Friday approved a nasal spray flu vaccine for self-administration. Starting next fall, AstraZeneca's FluMist, which was authorized in 2003 to be administered by a health care provider, will be available to ordinary Americans through an online pharmacy.

Finanznachrichten · 1d

AstraZeneca PLC: FluMist approved for self-administration in US

FluMist approved for self-administration in the US Only influenza vaccine approved for self- or caregiver-administration at home, expanding options for influenza protection FluMist

2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market Again

Instead of four equal quarterly distributions, AstraZeneca insists on two payments per year, with a greater portion announced ...

FiercePharma13d

AstraZeneca's Alexion loses $130M to Syntimmune shareholders in post-merger payment suit

When AstraZeneca’s Alexion picked up rare disease specialist Syntimmune in 2018 for $ | A Delaware judge agreed that ...

GlobalData on MSN11d

AstraZeneca/Daiichi’s ADC shows better survival for nonsquamous NSCLC patients

Datopotamab deruxtecan, developed under a collaboration between AstraZeneca and Daiichi Sankyo, elicited higher overall ...

STAT6d

Pharmalittle: We’re reading about an AstraZeneca bladder cancer drug, Genentech anxiety, and more

An AstraZeneca immunotherapy improved survival rates in patients with bladder cancer, results that could reshape treatment of ...

FiercePharma4d

AstraZeneca's Fasenra plays catch-up with GSK's Nucala, gaining FDA nod for rare autoimmune disease

Since GSK’s Nucala and AstraZeneca’s Fasenra were approved two years apart ... Nucala gained nods from the FDA to treat ...

ASCO 2020: ADAURA trial demonstrates a 79% reduction in the risk of death with Tagrisso in the adjuvant setting

ADAURA Trail Results Reveal 79% Reduction in Risk of Death with Tagrisso The eagerly anticipated data from the Phase III ADAURA trial were announced on Sunday 31 May at the virtual ASCO 2020 ...

Morningstar4d

AstraZeneca PLC ADR AZN

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

EuropaWire13d

AstraZeneca Pioneers Low-Impact Inhalers with Eco-Friendly Breztri Transition

AstraZeneca has completed clinical studies to transition Breztri, its inhaled treatment for COPD, to a next-generation ...

Yahoo Finance5d

AstraZeneca PLC (AZNA.VI)

September 16, 2024--Updated results from the HIMALAYA Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab ... ADAURA ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results